Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$21.06 USD
-0.60 (-2.77%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $21.05 -0.01 (-0.05%) 7:00 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 701 - 720 ( 722 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals -Q2 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4 Financials Uneventful. We See a Robust EXPAREL Launch the Week of April 9. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
3-Month Delay in EXPAREL Launch Results in Only Slight Revenue Impact But Provides Additional Time for Manufacturing and Pre-Launch Activities.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
LIFE SCIENCES: 2012 Life Sciences and Healthcare Preview: Macro and Sector Trends; Catalysts; Top Picks
Provider: WEDBUSH SECURITIES INC.
Analyst: JAMES S
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
We See Reduced Competitive Risk as Potential Competitor, Posidur, Misses Phase 3 Endpoint. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL Pivotal Trial Data Published in Medical Journal Ahead of Anticipated Launch in January 2012. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Recent Financing Extends Cash Runway Through Commercial Launch and Potential Breakeven. Reiterate OUTPERFORM and Adjusting FV to $16.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL Approved For Postsurgical Pain Management and Launch Expected In January 2012
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
We Are Optimistic for Potential EXPAREL Approval by the PDUFA Date of this Friday, October 28th. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
New Data Shows Reduction in Opioid Burden with Exparel
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Exparel Use in Plastic Surgery Highlighted at Medical Conference
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Commercial Strategy Progresses with New Marketing and Logistics Agreements Ahead of Important October 28 PDUFA Date for Exparel
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of September 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Exparel PDUFA Date Extended by Three Months to October 28th
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Presentation of program-wide safety data for Exparel supports potential FDA approval, in our view.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1 Financials: Pre-Launch Activities Continue to Progress Ahead of July 28 PDUFA for Exparel
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R